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Background
Undetectable HCV-RNA at week 4 of therapy (RVR) is
one of the best predictors of SVR in patients with
chronic hepatitis C. However, there is scarce informa-
tion about the variables influencing the achievement of
SVR in patients without RVR.
Methods
A prospective study in which HIV-HCV coinfected
patients were randomized to receive either pegylated
IFNa-2a 180 µg/week plus ribavirin (RBV) at two differ-
ent doses: i) 1000-1200 mg/day (arm A) or ii) 2000 mg/
day plus erythropoietin (EPO) from baseline to week 4
(arm B), was conducted. Patients not achieving RVR
prolonged therapy to 48 weeks for G2-3 and to 72 for
G1-4. Liver fibrosis was measured using transient elasto-
metry, being liver stiffness values ≥9.5 kPa as reflect of
Metavir ≥F3. RBV trough concentrations at week 4 and
pharmacogenetic studies including polymorphisms at
the ITPA, ENT1 and IL28B genes were also performed.
Variables associated to SVR in those not achieving RVR
were examined.
Results
A total of 108 patients had reached the end of follow-up
at the time the analysis (82% males; mean age, 43 years;
mean baseline HCV-RNA, 6.4 log IU/mL; 91% HCV
G1-4; 50% METAVIR ≥F3 estimates; mean CD4 count,
566 cells/µL; 93% on HAART and 84% with plasma
HIV-RNA <50 copies/mL). In the on-treatment analysis
33% achieved SVR (31% vs 60% for G1-4 and G2-3;
p<0.05; 42% vs 23% for patients with Hb drop at week 4
≥2 vs <2 g/dL; p=0.04; 26% vs 43% for ≥F3 vs <F3;
p=0.12; 57% vs 14% for patients with undetectable vs
detectable HCV-RNA at week 12; p<0.001; 59% vs 18%
for patients completing vs non-completing treatment
prolongation; p<0.001). No differences in SVR rates
were found comparing arms A vs B. Mean baseline
HCV-RNA in patients with vs without SVR were 6.2 vs
6.5 log IU/mL, respectively [p=0.02]. The SVR rate was
57% vs 25% in IL28B CC vs CT/TT carriers [p=0.04].
No significant differences were found for other genetic
polymorphisms examined. In the multivariate analysis
(OR [95% CI], p) undetectable HCV-RNA at week 12
(5 [2-14], 0.001) and completing treatment prolongation
(4 [1.5-12], 0.005) were the only independent predictors
of SVR. IL28B CC was not included in the final analysis
as it was only available for 42 patients.
Conclusions
Optimizing duration of HCV therapy (48 weeks for G2-
3 and 72 weeks for G1-4) in HIV/HCV co-infected
patients without RVR can clearly improve the SVR rate.
Moreover, achievement of undetectable HCV-RNA at
week 12 is a strong predictor of SVR in this population.
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